Tandemai Announces $25 Million Seed &Amp; Pre-Series A Financing Led By Orbimed And Chengwei Capital

Dec 22, 2021•over 3 years ago

Amount Raised

$25 Million

Round Type

seed

Suzhou

Description

TandemAI today announced it has raised $25 million in Seed and pre-Series A financing to advance its proprietary computational platform and expansion of its wet lab operations. The company will tightly integrate the computational platform with wet labs for biophysics, medicinal chemistry, and biology in order to accelerate the design and optimization of drug candidates for partners. The round was led by OrbiMed and Chengwei Capital.

Company Information

Company

Tandem Ai

Location

Suzhou, Jiangsu, China

About

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community. Learn more at www.tandemai.com

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Tandemai Announces $25 Million Seed &Amp; Pre-Series A Financing Led By Orbimed And Chengwei Capital

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information